Intestinal toxicity to CTLA-4 blockade driven by IL-6 and myeloid infiltration
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
Immune checkpoint blockade (ICB) has revolutionized cancer treatment, yet quality of life and continuation of therapy can be constrained by immune-related adverse events (irAEs). Limited understanding of irAE mechanisms hampers development of approaches to mitigate their damage. To address this, we examined whether mice gained sensitivity to anti-CTLA-4 (αCTLA-4)–mediated toxicity upon disruption of gut homeostatic immunity. We found αCTLA-4 drove increased inflammation and colonic tissue damage in mice with genetic predisposition to intestinal inflammation, acute gastrointestinal infection, transplantation with a dysbiotic fecal microbiome, or dextran sodium sulfate administration. We identified an immune signature of αCTLA-4–mediated irAEs, including colonic neutrophil accumulation and systemic interleukin-6 (IL-6) release. IL-6 blockade combined with antibiotic treatment reduced intestinal damage and improved αCTLA-4 therapeutic efficacy in inflammation-prone mice. Intestinal immune signatures were validated in biopsies from patients with ICB colitis. Our work provides new preclinical models of αCTLA-4 intestinal irAEs, mechanistic insights into irAE development, and potential approaches to enhance ICB efficacy while mitigating irAEs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2
Love, M. I., Huber, W., & Anders, S. (2014) · Genome Biology · doi:10.1186/s13059-014-0550-8 · Cited by 95,106
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors
Routy, B., Le Chatelier, E., Derosa, L., Duong, C. P. M., Alou, M. T., Daillère, R., Fluckiger, A., Messaoudene, M., Rauber, C., Roberti, M. P., et al. (2018) · Science · doi:10.1126/science.aan3706 · Cited by 5,671 · cited 3×
“Recent work has generated important correlatives between specific taxa and response or toxicity with ICB treatment (Andrews et al., 2021; Chaput et al., 2017; Gopalakrishnan et al., 2018b; McCulloch et al., 2022; Routy et al., 2018).”
Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
Postow, M. A., Sidlow, R., & Hellmann, M. D. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1703481 · Cited by 4,849
Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients
Gopalakrishnan, V., Spencer, C. N., Nezi, L., Reuben, A., Andrews, M. C., Karpinets, T. V., Prieto, P. A., Vicente, D., Hoffman, K., Wei, S. C., et al. (2018) · Science · doi:10.1126/science.aan4236 · Cited by 4,812 · cited 3×
“Recent work has generated important correlatives between specific taxa and response or toxicity with ICB treatment (Andrews et al., 2021; Chaput et al., 2017; Gopalakrishnan et al., 2018b; McCulloch et al., 2022; Routy et al., 2018).”
Self-citationNivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
Motzer, R. J., Tannir, N. M., McDermott, D. F., Arén Frontera, O., Melichar, B., Choueiri, T. K., Plimack, E. R., Barthélémy, P., Porta, C., George, S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1712126 · Cited by 4,656 · cited 2×
“…checkpoint mechanisms has provided the most significant breakthrough in cancer treatment in the past decade with demonstrated clinical success in controlling a variety of aggressive tumors (Curran et al., 2010; Hellmann et al., 2018; Hodi et al., 2018; Leach et al., 1996; Motzer et al., 2018).”
McGinnis, C. S., Murrow, L. M., & Gartner, Z. J. (2019) · Cell Systems · doi:10.1016/j.cels.2019.03.003 · Cited by 4,521
Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota
Vétizou, M., Pitt, J. M., Daillère, R., Lepage, P., Waldschmitt, N., Flament, C., Rusakiewicz, S., Routy, B., Roberti, M. P., Duong, C. P. M., et al. (2015) · Science · doi:10.1126/science.aad1329 · Cited by 3,488 · cited 1×
“…colitis The intestinal microbiome is linked with antitumor response to ICB, irAEs, and non-ICB-associated intestinal inflammation (Cheng et al., 2020; Dubin et al., 2016; Gopalakrishnan et al., 2018a; Gopalakrishnan et al., 2018b; McCulloch et al., 2022; V´etizou et al., 2015; Wang et al., 2018).”
Fundamental Mechanisms of Immune Checkpoint Blockade Therapy
Wei, S. C., Duffy, C. R., & Allison, J. P. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0367 · Cited by 3,088
Self-citationNivolumab plus ipilimumab in lung cancer with a high tumor mutational burden
Hellmann, M. D., Ciuleanu, T.-E., Pluzanski, A., Lee, J. S., Otterson, G. A., Audigier-Valette, C., Minenza, E., Linardou, H., Burgers, S., Salman, P., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801946 · Cited by 3,063 · cited 2×
“…checkpoint mechanisms has provided the most significant breakthrough in cancer treatment in the past decade with demonstrated clinical success in controlling a variety of aggressive tumors (Curran et al., 2010; Hellmann et al., 2018; Hodi et al., 2018; Leach et al., 1996; Motzer et al., 2018).”
Cited by
Immune checkpoint therapy—current perspectives and future directions
Sharma, P., Goswami, S., Raychaudhuri, D., Siddiqui, B. A., Singh, P., Nagarajan, A., Liu, J., Subudhi, S. K., Poon, C., Gant, K. L., et al. (2023) · Cell · doi:10.1016/j.cell.2023.03.006 · Cited by 1,206
Self-citationHalsey, T. M., Thomas, A. S., Hayase, T., Ma, W., Abu-Sbeih, H., Sun, B., Parra, E. R., Jiang, Z.-D., DuPont, H. L., Sanchez, C., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.abq4006 · Cited by 161
Self-citationGao, Y., Xu, P., Sun, D., Jiang, Y., Lin, X.-L., Han, T., Yu, J., Sheng, C., Chen, H., Hong, J., et al. (2023) · Cancer Research · doi:10.1158/0008-5472.can-23-0605 · Cited by 116
Elkrief, A., Waters, N. R., Smith, N., Dai, A., Slingerland, J., Aleynick, N., Febles, B., Gogia, P., Socci, N. D., Lumish, M., et al. (2024) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-23-0498 · Cited by 48
Metadata
- Authors
- Zhou, Y., Medik, Y. B., Patel, B., Zamler, D. B., Chen, S., Chapman, T., Schneider, S., Park, E. M., Babcock, R. L., Chrisikos, T. T., Kahn, L. M., Dyevoich, A. M., Pineda, J. E., Wong, M. C., Mishra, A. K., Cass, S. H., Cogdill, A. P., Johnson, D. H., Johnson, S. B., Wani, K., Ledesma, D. A., Hudgens, C. W., Wang, J., Wadud Khan, M. A., Peterson, C. B., Joon, A. Y., Peng, W., Li, H. S., Arora, R., Tang, X., Raso, M. G., Zhang, X., Foo, W. C., Tetzlaff, M. T., Diehl, G. E., Clise-Dwyer, K., Whitley, E. M., Gubin, M. M., Allison, J. P., Hwu, P., Ajami, N. J., Diab, A., Wargo, J. A., & Watowich, S. S.
- Venue
- Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2022-11-11
- Volume
- 220
- Issue
- 2
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- OpenAlex
- W4308784994
- Cited by
- 62
- References
- 35
- FWCI
- 4.53
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.